Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:celiac [07.20.2019]
sallieq [recent research]
home:diseases:celiac [04.26.2020] (current)
sallieq [recent research]
Line 75: Line 75:
 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​ 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​
 (({{pubmed>​long:​30594690}})) (({{pubmed>​long:​30594690}}))
 +
 +Research associated with J Tye-Din ​  ​(({{pubmed>​long: ​   20650871}})) ,  (({{pubmed>​long:​17629515}})) ,  (({{pubmed>​long:​888}})) ,  (({{pubmed>​long: ​   19942485}})) ,  (({{pubmed>​long:​23981538}})) ,  (({{pubmed>​long:​16099789}})) ,  (({{pubmed>​long:​888}})) ​
 +
 +
  
 {{tag>​diseases }} {{tag>​diseases }}
home/diseases/celiac.txt · Last modified: 04.26.2020 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.